Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation

Yuan Liu, Qin Xie, Huixian Zhou, Krushi Shah and Siyuan Song

AI Med, 2026, vol. 2, issue 1

Abstract: Chronic neuropathic pain affects 7–10% of the global population and imposes a substantial socioeconomic burden, yet existing pharmacological options remain inadequate in efficacy and burdened by systemic toxicity. Antibody-drug conjugates (ADCs) — engineered to deliver neuromodulatory payloads selectively to peripheral nociceptors — represent a compelling but unexplored therapeutic modality; no clinical-stage pain ADC currently exists. To the best of our knowledge based on a structured literature search (January 2000–March 2025) and targeted updates through 6 June 2026, this review provides a systematic and comprehensive conceptual framework mapping AI methodologies validated in oncology ADC development onto the unique challenges of chronic neuropathic pain. The framework spans five pipeline stages: multi-omics integration and graph neural networks for nociceptor-selective target prioritization (Nav1.7, TRPV1, P2X3, TrkA, CGRP receptor, ASIC3); structure prediction and protein language models for antibody engineering against transmembrane pain targets; generative AI for neuromodulatory payload design; deep learning for neural tissue pharmacokinetics and neurotoxicity prediction; and AI-driven patient stratification for precision clinical trial design. A unique three-layer optimization challenge — neural selectivity, analgesic potency, and systemic safety — distinguishes pain ADC AI from oncology ADC AI and defines the core design constraints of this review. Clinical precedent from FDA-approved anti-CGRP pathway antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and Phase III anti-NGF antibody trials establishes that peripheral nociceptor-targeting biologics are both feasible and clinically active, providing the biological foundation for the pain-ADC concept. Realizing this framework requires curated pain-ADC datasets, interpretable AI, and closed-loop platforms incorporating dorsal root ganglion (DRG) organoids.

Keywords: antibody-drug conjugate; chronic neuropathic pain; artificial intelligence; dorsal root ganglion; Nav1.7; neuromodulation; drug discovery (search for similar items in EconPapers)
Date: 2026
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.ai-press.org/index.php/aimed/article/view/10-71423-aimed-20260606 Abstract page (text/html)
https://www.ai-press.org/index.php/aimed/article/d ... 23-aimed-20260606/10 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ayf:j00001:11

DOI: 10.71423/aimed.20260606

Access Statistics for this article

More articles in AI Med from AI Press Limited
Bibliographic data for series maintained by Ming Wu ().